Despite the availability of multiple anti-inflammatory agents and bronchodilators, considerable unmet need remains for patients with severe asthma. Typical treatments for this disease subpopulation include combination therapy regimens with several inhaled and/or oral therapies as well as biologics (Roche/Novartis’s Xolair, GSK’s Nucala, Teva’s Cinqair/Cinqaero, and—now—AstraZeneca’s Fasenra). Nevertheless, a sizable proportion of severe asthmatics remain inadequately controlled with currently available treatments. With quantitative insight into an assessment of the current level of unmet need in severe asthma by U.S. pulmonologists and allergists as well as European pulmonologists, we analyze remaining commercial opportunities and discuss how emerging therapies, such as Dupixent (Sanofi/Regeneron) and tezepelumab (Amgen/AstraZeneca), may capitalize on these opportunities.
- What clinical/nonclinical attributes are the key influencers of physicians’ prescribing decisions for severe asthma? For example, how important is the availability of a biomarker predictive of response to therapy?
- How do current asthma biologics and conventional combination therapy regimens perform on the aforementioned attributes? For example, which currently available biologic is viewed as the best performer at reducing asthma exacerbation rates?
- What are the prevailing areas of unmet need and where are the remaining commercial opportunities in severe asthma?
- What trade-offs across different clinical attributes and price are acceptable to physicians for a hypothetical new drug for severe asthma?
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, Germany.
Primary research: Survey of 33 U.S. pulmonologists, 27 U.S. allergists, and 30 European pulmonologists fielded in March 2018.
Key companies: GlaxoSmithKline, AstraZeneca, Teva, Regeneron, Sanofi, Boehringer Ingelheim, Amgen, Novartis, Roche, Chiesi.
Key drugs: Advair/Seretide, Symbicort, Dulera, Foster, Breo/Relvar, Flutiform, Spiriva, Xolair, Nucala, Cinqair/Cinqaero, Fasenra, oral prednisone.